Craft

Theriva Biologics

Stock Price

$1.5

2024-10-29

Market Capitalization

$3.3 M

2024-10-29

Theriva Biologics Summary

Company Summary

Overview
Theriva Biologics (formerly Synthetic Biologics) is a clinical-stage company that develops oncolytic virus therapeutics. It focuses on immune modulation to treat conditions with limited therapeutic options, such as pancreatic cancer, colorectal cancer, and other solid tumors.
Type
Public
Status
Active
Founded
1986
HQ
Rockville, MD, US | view all locations
Website
https://therivabio.com/
Cybersecurity rating
Sectors

Key People

  • Jeffrey J. Kraws, Chairman

    • Steven Shallcross

      Steven Shallcross, Chief Executive Officer, Chief Financial Officer, Director

    • Manel Cascallo

      Manel Cascallo, General Director, EU Subsidiary

    • Jeffrey Wolf, Director

      LocationsView all

      2 locations detected

      • Rockville, MD HQ

        United States

        9605 Medical Center Dr. Suite 270

      • Barcelona, CT

        Spain

        Carrer Torrent de Can Ninou, naus 5-6

      Theriva Biologics Financials

      Summary Financials

      Revenue (Q1, 2026)
      $300.0K
      Net income (Q1, 2026)
      ($2.0M)
      Cash (Q1, 2026)
      $14.4M
      EBIT (Q1, 2026)
      ($2.1M)
      Enterprise value
      ($7.4M)

      Footer menu